Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC
2. Furmonertinib superior to gefitinib as first-line treatment for EGFR-mutated NSCLC
3. Atezolizumab efficacious across high PD-L1 expressers with stage II-IIIA NSCLC
4. Perioperative survival after a bilobectomy: respect the middle lobe